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Genetic deletion of mGlu2 metabotropic
glutamate receptors improves the short-
term outcome of cerebral transient focal
ischemia
Federica Mastroiacovo1, Slavianka Moyanova1, Milena Cannella1, Anderson Gaglione1, Remy Verhaeghe1,
Giovanna Bozza1, Michele Madonna1, Marta Motolese1, Anna Traficante1, Barbara Riozzi1, Valeria Bruno1,2,
Giuseppe Battaglia1, David Lodge3 and Ferdinando Nicoletti1,2*
Abstract: We have recently shown that pharmacological blockade of mGlu2 metabotropic glutamate receptors
protects vulnerable neurons in the 4-vessel occlusion model of transient global ischemia, whereas receptor
activation amplifies neuronal death. This raised the possibility that endogenous activation of mGlu2 receptors
contributes to the pathophysiology of ischemic neuronal damage. Here, we examined this possibility using two
models of transient focal ischemia: (i) the monofilament model of middle cerebral artery occlusion (MCAO) in mice,
and (ii) the model based on intracerebral infusion of endothelin-1 (Et-1) in rats. Following transient MCAO, mGlu2
receptor knockout mice showed a significant reduction in infarct volume and an improved short-term behavioural
outcome, as assessed by a neurological disability scale and the “grip test”. Following Et-1 infusion, Grm2 gene
mutated Hannover Wistar rats lacking mGlu2 receptors did not show changes in the overall infarct volume as
compared to their wild-type counterparts, although they showed a reduced infarct area in the agranular insular
cortex. Interestingly, however, mGlu2 receptor-deficient rats performed better than wild-type rats in the adhesive
tape test, in which these rats did not show the laterality preference typically observed after focal ischemia. These
findings support the hypothesis that activation of mGlu2 receptors is detrimental in the post-ischemic phase, and
support the use of mGlu2 receptor antagonists in the experimental treatment of brain ischemia.
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Introduction
Metabotropic glutamate (mGlu) receptors have been
implicated in mechanisms of neurodegeneration/neuro-
protection, and are promising drug targets for the treat-
ment of acute and chronic neurodegenerative disorders
[1]. It was believed for many years that group-II mGlu
receptor agonists could produce neuroprotection by ac-
tivating both mGlu2 and mGlu3 receptors [1], until it
was shown in mouse primary cortical cultures that the
protective activity of the mGlu2/3 receptor agonist,
LY379268, against excitotoxic neuronal death was largely
mediated by the activation of glial mGlu3 receptors [2].
The unexpected findings that cultured neurons lacking
mGlu2 receptors were more resistant to excitotoxic death
and that systemic administration of LY379268 was pro-
tective against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine neurotoxicity only in mGlu2 receptor knockout mice
[2] raised the possibility that mGlu2 receptors facilitated
neuronal death. This hypothesis was supported by a
further in vitro study in which neurotoxicity caused by β-
amyloid peptide was amplified by a selective positive
allosteric modulator (PAM) of mGlu2 receptors, which
was inactive when neurons lacked mGlu2 receptors [3].
The unexpected neurotoxic activity of mGlu2 receptors
contributes to explain the contrasting data obtained with
orthosteric mGlu2/3 receptor agonists in in vitro models
of excitotoxic neuronal death [4–6], and the suboptimal
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effect of these drugs in animal models of global and focal
brain ischemia [7–10].
Using the 4-vessel occlusion model of transient global
ischemia, we found that post-ischemic systemic treat-
ment with a selective negative allosteric modulator
(NAM) of mGlu2 receptors protected vulnerable hippo-
campal CA1 pyramidal neurons, whereas treatment
with a PAM of mGlu2 receptors extended the damage
to resistant CA3 pyramidal neurons [12]. The possibil-
ity that mGlu2 receptor NAMs may be used as protect-
ive agents in brain ischemia is particularly promising
because mGlu2 receptor NAMs are currently under
preclinical and clinical development for the treatment
of major depression, and show cognitive enhancing
properties associated with a good profile of safety and
tolerability [13]. However, transient global ischemia in
rodents represents a model of brain hypoperfusion as-
sociated with cardiac arrest or hypotensive shock, but
has no translational value for drug development in the
treatment of stroke. It is therefore necessary to extend
the study of mGlu2 receptors to models of transient
focal ischemia that more closely mimic thrombo-
embolic stroke in humans, such as the models of transi-
ent middle cerebral artery occlusion (MCAO) induced
by filament insertion in mice [14] and intracerebral
endothelin-1 (Et-1) infusion in rats [15]. We used these
two models respectively in mGlu2 receptor knockout
mice (mGlu2−/−) and in Hannover Wistar rats (Han
Wistar rats) [16, 17] lacking mGlu2 receptors to exam-
ine the influence of mGlu2 receptors on the short-term
histological and behavioural outcome of transient focal
ischemia.
Results
Infarct volume and improved behavioral outcome in
mGlu2 receptor knockout mice subjected to transient
MCAO
Transient MCAO in mGlu2+/+ mice caused a rapid devel-
opment of ischemic infarct, which involved the striatum
and a large proportion of the surrounding cerebral cortex.
The ischemic infarct was detectable as early as 3 h after
reperfusion, and reached its maximal size at 24–48 h after
reperfusion (Fig. 1a). To examine whether MCAO could
induce adaptive changes in the expression of mGlu2 re-
ceptors, we measured mGlu2 receptor protein levels by
Western blot analysis in the cerebral cortex at 6 h after re-
perfusion. Measurements were performed in the core of
the infarct area, in the neighboring cortical area, in the
corresponding regions of the contralateral intact hemi-
sphere, and in the corresponding regions of sham oper-
ated mice (see Fig. 1b). Western blot analysis showed a
band at about 100 kDa corresponding to mGlu2 receptor
monomers, and a higher molecular size band, correspond-
ing to receptor dimers. The identity of the two bands was
confirmed using reference tissue from mGlu2−/− mice
(see immunoblot in Fig. 1c, d). mGlu2 receptor protein
levels were not altered in the core region of the ische-
mic cerebral cortex as compared to the contralateral
cortex or to the cortex of non-ischemic mice (Fig. 1c).
In contrast, a slight but significant increase in mGlu2
receptor protein levels was seen in the cortical region
neighboring the ischemic core as compared to the
contralateral region and to the corresponding region of
non-ischemic mice (Fig. 1d).
We next examined whether the lack of mGlu2 receptors
could affect the extent of the ischemic lesion in mice sub-
jected to transient MCAO induced by filament insertion
into the external carotid artery. Macroscopic analysis of
cerebrovascular anatomy did not show differences be-
tween mGlu2−/− mice and their wild-type counterparts
(mGlu2+/+). In addition, MCAO reduced regional cerebral
blood flow (rCBF) to a similar extent in the two genotypes
(Fig. 2a, b). The volume of ischemic infarct, evaluated by
Nissl staining at 48 h after reperfusion, was significantly
smaller in mGlu2−/− mice, as compared to mGlu2+/+ mice
(Fig. 2c, d).
In mGlu2+/+ mice, MCAO induced a neurological
deficit with a score of about 2 (weakness and circling
behavior towards the contralateral site) at 2 and 24 h after
reperfusion. The deficit was attenuated at 48 h. The
neurological deficit was significantly reduced in mGlu2−/−
at 24 h (Fig. 3a), but not at 48 h after ischemia.
The most striking difference between the two genotypes
was observed when muscular strength of the left and right
forelimbs was measured by the grip test. mGlu2+/+ mice
showed a marked asymmetry in muscular strength, which
was reduced in the contralateral forepaw at 2, 24, and
48 h after reperfusion. No asymmetry was found in
mGlu2−/− mice at any time point (Fig. 3b). The loss of
muscular strength was significantly greater in mGlu2+/+
mice than in mGlu2−/− mice at 2 and 24 h after reperfu-
sion (Fig. 3b).
To exclude the possibility that mGlu2−/− mice could be
protected against ischemic damage because of compensa-
tory changes in other mGlu receptor subtypes, we mea-
sured the transcripts of mGlu1, mGlu3, mGlu4, mGlu5,
mGlu7, and mGlu8 receptors in the cerebral cortex and
striatum of mGlu2−/− mice and their wild-type littermates.
We found no changes in the transcripts of the various
mGlu receptor subtypes with the exception of the tran-
script of mGlu7 receptors, which was significantly reduced
in the striatum of mGlu2−/− mice (Fig. 4).
Short-term outcome of transient focal ischemia in wild-type
and Grm2 mutant Han Wistar rats
We could identify Han Wistar rats carrying a single point
mutation of exon 3 of the Grm2 gene, which results into a
stop codon at Cys407 and the lack of functional mGlu2
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receptors [17] (Fig. 5a). Wild-type (WT) and Grm2 mu-
tant Han Wistar rats were subjected to transient focal is-
chemia induced by unilateral injection of Et-1 near the
MCA of the left hemisphere (Fig. 5b). MCAO caused a
large infarct volume detected after 72 h, which did not dif-
fer between WT and Grm2 mutant rats (Fig. 5c, d). There
was no difference in the infarct volume in the cerebral
cortex and striatum between ischemic WT and Grm2 mu-
tant Han Wistar rats, although a trend to a reduction in
Grm2 mutant Han Wistar rats was observed (Fig. 5e, f ).
We also measured infarct area in different cortical sub-
regions in a single section at +0.2 mm from bregma,
corresponding to the site of Et-1 injection (Fig. 6a). No
significant differences in the infarct area between WT and
Grm2 mutant rats were found in the forelimb region
(S1FL), dysgranular region (S1DZ), and upper lip region
(S1ULp) of the primary somatosensory cortex and in the
secondary somatosensory cortex (S2) (Fig. 6b, e). Grm2
mutant rats showed a significant reduction in the infarct
area in the agranular insular cortex (AI) (Fig. 6g), and a
trend to a reduction in the granular and dysgranular insu-
lar cortex (GI/DI) and claustrum (Cl) (Fig. 6f, h).
Behavioral assessment with a neurologic examination
grading system that included a postural hang reflex test
(PHR) showed a moderate to severe neurologic deficit in
the right side of the body in both genotypes (Fig. 7a).
Statistical analysis of asymmetry expressed by the lateral-
ity index revealed a significant effect of ischemia at all
time sessions, as compared to pre-ischemic values (T0),
in both WT and Grm2 mutant rats (Fig. 7a).
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Fig. 1 mGlu2 Receptor protein levels in the cerebral cortex of mGlu2+/+ mice subjected to transient MCAO. Representative images of Nissl staining in
coronal sections of mice at 3, 6, 12 and 48 h after monofilament-induced transient MCAO are shown in (a). The boundaries of dissection of the core
region and the neighboring cortical region used for Western blot analysis are shown in (b). Immunoblot analysis of mGlu2 receptors in the cortical
region corresponding to the core and in the cortical regions neighboring the core (and the corresponding regions of the contralateral hemispheres
and of non-ischemic mice) is shown in (c) and (d), respectively. Densitometric data were obtained as the sum of the two bands corresponding to
monomers and dimers. Data are means + S.E.M. of 4–5 mice per group. *p < 0.05 as compared to all other groups (One-way ANOVA + Fisher’s
PLSD; F2,10 = 9.26)
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A difference between the two strains of rats emerged
from the analysis of preference and latency of removing
the adhesive tapes in the adhesive tape test (AT) test,
which is an active test of sensorimotor integration [18].
We found a large and significant increase in asymmetry in
both parameters of the AT test (preference and latency) in
WT rats at all times after Et-1 infusion (1, 24, and 72 h)
(Fig. 7b, c). This was indicative of a severe defect in an ac-
tive behavioral performance that requires sensorimotor in-
tegration [18]. Ischemia-induced asymmetry was much
less severe in Grm2 mutant rats than in the WT rats.
While the laterality index in the ischemic WT rats differed
significantly from that in sham-operated WT rats, the lat-
erality index in sham-operated and Et-1 infused Grm2
mutant rats was not significant different at all time points
(Fig. 7b, c). There was a significant difference in laterality
index between ischemic WT and Grm2 mutant rats at
72 h after Et-1 infusion (Fig. 7b, c).
Discussion
Neuroprotection remains an unmet need in the treatment
of ischemic stroke. Disappointing data were obtained in
clinical studies with ionotropic glutamate receptor antago-
nists in stroke owing to the strong impact of these drugs
on fast excitatory synaptic transmission in the CNS, and
the opposite role played by synaptic and extrasynaptic N-
methyl-D-aspartate (NMDA) receptors in neurodegenera-
tion/neuroprotection [1–19]. In addition, NMDA receptor
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antagonists impair mechanisms of activity-dependent
synaptic plasticity and may cause severe adverse effects,
such as psychotomimetic effects and intrinsic neurotox-
icity [1]. mGlu receptor ligands modulate synaptic
transmission, and are therefore considered as more
valuable candidate targets for neuroprotective drugs.
The mGlu receptor ligands developed so far for the
treatment of CNS disorders have shown a good profile
of safety and tolerability, which may reflect the modula-
tory role of mGlu receptors in synaptic transmission
and activity-dependent synaptic plasticity.
Our interest in mGlu2 receptors as targets for neuro-
protective drugs was raised by in vitro studies showing
that the neuroprotective activity of mGlu2/3 receptor
agonists against NMDA or β-amyloid toxicity was
largely mediated by mGlu3 receptors, and that activa-
tion of mGlu2 receptors was instead neurotoxic [2, 3].
These findings laid the groundwork for an in vivo study
in which we examined mGlu2 receptor expression in
vulnerable and non-vulnerable hippocampal subregions
and the effects of selective mGlu2 receptor ligands in
the 4-vessel occlusion model of transient global ische-
mia. We found that mGlu2 receptor mRNA levels were
lower in the resistant hippocampal CA3 region than in
the vulnerable CA1 region, and that transient global is-
chemia selectively down-regulated mGlu2 receptors in
the CA1 region [12]. In addition, we found that sys-
temic post-ischemic treatment with a selective mGlu2
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receptor NAM protected CA1 neurons against ischemic
damage, whereas treatment with a selective mGlu2 recep-
tor PAM extended the damage to CA3 neurons [12].
We have now studied the role of mGlu2 receptors in is-
chemic damage and the resulting behavioral impairment
using two models of transient focal ischemia: (i) the
monofilament model in mice; and, (ii) the Et-1 model in
rats. In mice, transient MCAO did not induce early
changes in the expression of mGlu2 receptors in a cortical
area corresponding to the ischemic core, whereas it
caused a significant increase in mGlu2 receptor protein
levels in the neighboring cortical area that likely includes
part of the penumbra region. This increase was small and
its significance in the pathophysiology of ischemic damage
is uncertain. However, these data further suggest that the
ischemic insult causes adaptive changes in the expression
of mGlu2 receptors.
Infarct size was significantly reduced in ischemic mGlu2
−/− mice as compared to their WT counterparts, but not
in Grm2 mutant rats, although the extent of ischemic
damage was similar in mice and rats following transient
MCAO. The easiest explanation for this apparent discrep-
ancy is that it is not the lack of mGlu2 receptors that pro-
tects mGlu2−/− mice against damage caused by transient
focal ischemia. Compensatory changes in the expression
of other receptors or membrane transporters might render
these mice less vulnerable to ischemic damage. It was
logical to examine whether expression of other mGlu
receptor subtypes was abnormal in the cerebral cortex
and striatum of mGlu2−/− mice. We found no changes in
the transcripts of mGlu receptor subtypes that have
been implicated in mechanisms of neurodegeneration/
neuroprotection, such as mGlu1, mGlu3, mGlu4, and
mGlu5 receptors [1, 20, 21]. In contrast, the transcript
of the mGlu7 receptors was substantially reduced in the
striatum - but not in the cerebral cortex - of mGlu2−/−
mice. We do not believe that this reduction contributes to
reduce vulnerability of mGlu2−/− mice to ischemic damage
because the mGlu7 receptor negatively modulates the ac-
tivity of NMDA receptors [22], and, therefore, its activa-
tion is potentially neuroprotective. No need to say that
possible alterations in other neurotransmitter receptors,
membrane transporters or intracellular proteins might
contribute to the reduced vulnerability of mGlu2−/− mice
to ischemic damage. This hypothesis warrants further
investigation.
Interestingly, the absence of mGlu2 receptors improved
the behavioral outcome of focal ischemia in both mice and
rats. In mGlu2−/− mice neurological disability was signifi-
cantly attenuated at 24 h, but not at 48 h after ischemia,
and the defect in the grip strength in the contralateral
forearms was prevented in these mice at all time points
after ischemia. Grm2 mutant rats lacking mGlu2 receptors
showed a substantial improvement in their performance
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in the AT test. This is an active test of sensorimotor in-
tegration involving the somatosensory cortex, antero-
medial cortex, and striatum [23, 24]. The AT test, also
called sensorimotor asymmetry test, models the tactile
neglect in patients with frontal and parietal cortical
lesions [25, 26]. We were surprised to find that ische-
mic Grm2 mutant rats showed less asymmetry in the
tape test as compared to WT rats, in spite of the simi-
lar extent of ischemic infarct in the two genotypes.
Ischemic Grm2 mutant rats showed a significant reduc-
tion of the infarct area in the dorsal portion of the AI, and
a trend to a reduction in the granular and GI/DI and Cl.
The Cl is involved in the processing of sensorimotor and
visuomotor information [27]. The dysgranular portion of
the insular cortex receives projections from the secondary
somatosensory area and, therefore, is also involved in
somatosensory processing [28]. In contrast, the agranular
portion of the insular cortex, which is part of the pain
(See figure on previous page.)
Fig. 5 No difference in the infarct volume between WT and Grm2 mutant rats subjected to MCAO. WT and Grm2 mutant chromatograms from
Sanger sequencing (a); scheme design of a coronal brain section at bregma level + 0.2 mm [30] (b); representative images of brain Nissl staining
in non-ischemic (sham-operated rat), WT and Grm2 mutant Han Wistar rats subjected to transient MCAO (c); total infarct volume and infarct
volumes in the cerebral cortex and striatum are shown in (d), (e), and (f), respectively. Bars represent means + S.E.M. of 8 rats per group
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matrix, is involved in nociceptive processing [29], and may
play a role in decision-making behavior under risk [30].
Of note, activation of the insular cortex is associated with
orofacial movements [31], which are involved in sensori-
motor integration during performance of adhesive tape re-
moval. It is possible that in the post-ischemic period the
application of a tape in the forepaw is processed as an
aversive event and that activation of the AI is required for
the decision to rapidly remove the tape. If so, the reduced
infarct area in the AI might contribute to the better per-
formance of mGlu2−/− mice in the AT test. However, this
is not fully convincing, and the combination of mouse and
rat data suggest that, at least in models of focal ischemia,
endogenous activation of mGlu2 receptors may not be
critical for the development of ischemic neuronal damage,
but becomes detrimental for functional recovery at short
intervals after reperfusion. The use of selective mGlu2
receptor ligands will be a necessary step for an in-depth
investigation of the role played by mGlu2 receptors in
models of transient focal ischemia.
Conclusions
Our data suggest that endogenous activation of mGlu2
receptors is detrimental for the short-term outcome of
transient focal ischemia, and support the hypothesis that
pharmacological blockade of mGlu2 receptors is a valu-
able strategy for the treatment of brain ischemia. It is
possible that endogenous activation of mGlu2 receptors
contributes to dysfunction of synaptic plasticity and
network activity underlying the imbalance between the
two hemispheres in the early post ischemic phase, and that
mGlu2 receptor antagonists correct this dysfunction
thereby facilitating functional recovery. This is consistent
with the “therapeutic” effect of mGlu2 receptor antagonists
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in experimental animal models of cognitive dysfunction as-
sociated with major depression [13].
The reduced infarct volume observed in mGlu2−/−
mice subjected to transient focal ischemia leaves open
the possibility that endogenous activation of mGlu2 re-
ceptors plays a permissive role in ischemic neuronal
damage, although data obtained in Grm2 mutant rats
are not consistent with this hypothesis. Further studies
are needed to better understand the precise role played
by mGlu2 receptors in the pathophysiology of ischemic
neuronal death.
Methods
Animals
mGlu2−/− mice on a C57Bl/6 genetic background were
kindly provided by Prof. Shigetada Nakanishi (Osaka,
Japan) and the colony was generated by homozygous
breeding. Han Wistar rats were purchased by Jackson
Laboratories (Bar Harbor, ME) and genotyped for the
presence of a stop codon mutation in the Grm2 gene
(see below). All animals were housed under standard
conditions with food and water ad libitum and a 12:12 h
light-dark cycle. Studies were performed in agreement
with the national and international guidelines and regu-
lations on animal care and use, and were approved by
the Neuromed Institutional Animal Care and Use Com-
mittee. All efforts were made to minimize animal suffer-
ing and to reduce the number of animals used.
Induction of transient MCAO in mice
Surgery, stroke induction, inclusion criteria
For measurements of mGlu2 receptor protein levels in the
cerebral cortex at 6 h following ischemia, we used 4 non-
ischemic and 5 ischemic C57Bl mice (20–25 g, b.w.). For
the study of focal ischemia in mice lacking mGlu2 recep-
tors we used 15 male mGlu2−/− mice and 11 age-matched
male mGlu2+/+ mice (20–25 g, b.w.). Transient MCAO
occlusion was induced as described by Nygren and Wie-
loch [14]. Briefly, anesthesia was induced by inhalation of
2.5% isoflurane in N2O/O2 (70:30) and maintained at 2%
by a face mask during the initial phase of surgery. Body
temperature was maintained at 37 °C using a heating pad
and controlled by a device connected with a temperature
probe inserted into the rectum. rCBF was monitored by a
flexible optical fiber connected to a laser Doppler (Peri-
Flux System 5000; Perimed, Jarfalla, Sweden) mounted on
the skull in correspondence of the MCA of the right
hemisphere. A silicon-coated filament (6–0 MCAO su-
ture, Doccol Corporation, Sharon MA) was introduced
into the internal carotid artery through an incision in the
external carotid artery. The filament was advanced until it
blocked the origin of the right MCA. Filament placement
was confirmed by a reduction in laser Doppler flow and
then, the isoflurane concentration was decreased to 1.5%
during the MCA occlusion (45 min). We have included
into analysis only mice with adequate occlusion, as deter-
mined by (1) rCBF reduction by at least 70% immediately
after filament placement; (2) sustained reduction of rCBF
for 45 min during occlusion; and, (3) complete recovery of
rCBF within 5 min after the filament was removed. There-
fore, 9 mGlu2+/+ and 9 mGlu2−/− mice were included in
statistical analysis for evaluation of the infarct volume.
Nine mGlu2+/+ and 11 mGlu2−/− mice were included in
statistical analysis for evaluation of neurological deficits.
Two mGlu2−/− mice died before performing the last be-
havioural test and therefore were not included in the in-
farct volume analysis. Seven mGlu2+/+ and 8 mGlu2−/−
mice were used for statistical analysis of the grip strength
test. After surgery, mice were injected with 0.5 ml of 5%
glucose subcutaneously, placed into an incubator (Com-
pact incubator, Thermo Scientific, AHSI, Bernareggio
(MI), Italy) at 37C° for 2 h, and then returned back to their
home cages. Animals were killed 48 h after MCAO and
their brains processed for histologic analysis.
Western blot analysis of mGlu2 receptors following
transient focal ischemia
Ischemic mice were killed by decapitation 6 h following
reperfusion. A cortical area corresponding to the ischemic
core (identified by the presence of a white boundary from
the surrounding tissue) and the neighboring cortical area
(see Fig. 1b) were dissected. The corresponding regions of
the contralateral hemispheres and the corresponding
regions of the cerebral cortex of sham-operated mice were
also dissected and stored frozen at −80 °C. Samples
homogenized at 4 °C in in a solution containing Tris-HCl
(pH 7.5), NaCl (50 mM), EDTA (5 mM), and an Ultra
Cruz Protease Inhibitor cocktail. Ten μg of proteins from
the supernatants were separated by 8% SDS polyacrila-
mide gel. Proteins were transferred on immuno-blot
PVDF membranes (Trans-Blot Turbo Transfer Systems,
Bio-Rad, Segrate, MI, Italy), which were incubated with a
polyclonal anti-mGlu2 receptor antibody (Abcam, Cam-
bridge, UK; 1:1000 in t-TBS) for 1 h at room temperature,
and then incubated for 1 more h with an anti-mouse sec-
ondary antibody (Calbiochem, San Diego, CA; 1:7000 in t-
TBS). For β-actin immunostaining, membranes were incu-
bated with a mouse monoclonal antibody (Sigma-Aldrich,
St Louis, MO; 1:50,000) in milk 5%, for 1 h at room
temperature, and then incubated for 1 more h with an
anti-mouse secondary antibody (Calbiochem; 1:7000 in t-
TBS). Immunostaining was revealed by the enhanced ECL
western blotting analysis system.
Behavioral tests
Evaluation of neurological function
We assessed the neurological function 1 d before (T0) and
at 2, 24, and 48 h after MCAO. Neurological function was
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scored by an investigator who was unaware of the geno-
type. We used the following grading system: 0 = no deficit;
1 = forelimb weakness; 2 = circling toward the affected,
contralateral (left) side; 3 = partial paralysis of the affected
side; 4 = no spontaneous motor activity [32].
Grip strength test
We assessed neuromuscular function by using the Grip
strength meter (2 Biological Instruments, Besozzo, VA,
Italy). The mouse voluntarily gripped a bar with either the
healthy (ipsilateral) or the affected (contralateral) forelimb
(FL) and pulled it backward. A mean of five trials was used
for analysis. We assessed muscular strength one day be-
fore ischemia (T0) and then, at 2, 24, and 48 h after
MCAO.
Quantitative analysis of the transcripts of mGlu1, −3, −4,
−5, −7, and −8 receptors in the cerebral cortex and
corpus striatum of non-ischemic mGlu2+/+ and mGlu2−/−
mice
Mice were killed by decapitation and the brain was
quickly removed; a cortical area corresponding to both
dissected regions in Fig. 1b, and the striatum were dis-
sected on ice and immediately frozen on liquid nitro-
gen, and stored at −80 °C. Total RNA was extracted
using Trizol reagent (Thermo Fisher Scientific, Waltham,
MA) according to manufacturer’s protocol. The RNA was
then treated with DNAse (Qiagen, Hilden, Germany) and
single strand cDNA was synthesized from 2 μg of total
RNA using superscript III (Thermo Fisher Scientific) and
random hexamers. Real-time PCR was performed as de-
scribed previously [12]. The following primers were used:
mGlu1 receptor, forward CATACGGAAAGGGGAAGT
GA and reverse AAAAGGCGATGGCTATGATG; mGlu3
receptor, forward CAGCAAGCTCCCTCTTTTGT and
Rev. GCTAAAAGAGCCCGTCACTG; mGlu4 receptor,
forward CTCCAGCCGCACGCTTGACA and reverse
GTAGGCCGAGTCCTGCCCGA; mGlu5 receptor, for-
ward ACGAAGACCAACCGTATTGC and reverse AGA
CTTCTCGGATGCTTGGA; mGlu7 receptor forward GG
TTTTCGTCAAGCCAGAGA and reverse ATCACTGA
GTTCAGGAGCCG; mGlu8 receptor forward CGGAATC
TGAACTTGCTCGG and reverse GGGGGAAGGCTT
TAGGGATTT; and TFRC (transferrin receptor protein-1)
forward CCAGTGTGGGAACAGGTCTT and reverse GC
ACCAACAGCTCCAAAGTC.
DNA extraction, PCR amplification and sanger sequencing
method for Han Wistar genotyping
DNA was extracted from the tail using Wizard genomic
DNA purification kit (Promega Corporation, Madison, WI)
according to manufacturer’s protocol. Fifty μg of DNA was
used for PCR amplification with following primers forward:
- 5′ GAACAGGAGTCAAAGATCATG 3′ and reverse: -
5′ CAGCACTATTACCGTCAAAC 3′. Thermal cycler
conditions were as follows:10 min at 95 °C, 35 cycles of de-
naturation (30 s at 95 °C), annealing (30 s at 55°) and exten-
sion (45 s at 72 °C); the extension was continued at 72 °C
for 7 min. Five μm of amplificated DNA was separated in a
2% agarose gel. All positive PCR products were purified by
Minielute PCR purification kit (Qiagen) by standard proce-
dures and 5 ng were sequenced with Big Dye Terminator v.
3.3 mix (Thermo Fisher Scientific) with forward primer by
using the following thermal cycler conditions program:
30 cycles of denaturation (10 s at 95°) annealing (5 s at 54°)
and extension (4 min 60°). Excess dye terminators were re-
moved using 2.0 spin kit (Qiagen); samples were electro-
phoresed on an ABI Prism 310 genetic analyzer (Applied
Biosystems, Foster City, CA) for genotype analysis.
Et-1-induced focal ischemia in mutant Han Wistar rats
Surgery, stroke induction, inclusion criteria
Twenty-six rats (weight 310 ± 40 g) were used: 13 Grm2
mutant Han Wistar and 13 WT. We used the Et-1
model of ischemia for the induction of transient focal is-
chemia. Rats were anaesthetized with an intramuscular
injection of a mix of ketamine (60 mg/kg) and xylazine
(12 mg/kg) dissolved into saline. A guide cannula was
placed at the following stereotaxic coordinates: AP +0.2;
ML +5.2 [33] avoiding to damage the dura mater. A
stainless steel wire was insert into the guide cannula to
plug it until the day of the Et-1 infusion. The guide can-
nula was secured to the skull with two supporting
screws and dental cement. We infused Et-1 (200 pmol in
3 μl of saline) 15–16 d after the surgery (a 5 days-treat-
ment with Baytril antibiotic, 0.2 ml/kg, s.c., 3 d of hand-
ling, 5 d of habituation to the experimental room and
experimental cage and training in the AT test, and 3 d
for control sessions before the Et-1 infusion). Et-1 was
infused in non-anesthetized rats by inserting an injection
cannula into the guide cannula. The tip of the injection
cannula targeted the piriform cortex approximately
0.2 mm from the MCA origin in the left hemisphere.
The same procedure was carried out in sham-operated
rats, infused with vehicle. We assessed the ischemia-
induced neurological deficits 10–15 min after Et-1 infu-
sion using the following 7-point scale: 0 = normal;
1 = held to face the table edge (to avoid vibrissae and
snout contacts with the table, the rat chin was supported
upward), the rat failed to place its right FL on the table
when we pushed the limb down with a soft bar (failed
proprioceptive dorsal FL placing); 2 = held and slightly
pushed to face the table edge from inside, the rat failed
to hold its FL on the edge of the table and slipped off
(failed proprioceptive ventral FL placing); 3 = suspended
by the tail, the rat twisted the torso upward; 4 = sus-
pended by the tail, the rat failed to extend the right FL
down, and the limb was flexed and/or clenched; 5 = after
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being placed on the table, the rat turned its body to the
right (spasmodic turning); 6 = the rat circled continu-
ously to the right after being placed on the table. Ische-
mia was considered as severe with scores from 11 to 21,
moderate, from 3 to 10; slight from 1 to 2. Twenty-two
rats (10 WT and 12 Grm2 Han Wistar mutant) satisfied
these inclusion criteria.
Behavioural tests
Neurological assessment and PHR test
We assessed spontaneous activity, symmetry in limb
movement, forepaw outstretching, and resistance to lat-
eral push and circling behavior [34]. In detail, we
assessed: (i) flexion and/or clenching of the digits and/
or full flexion of the wrist when the rat was suspended
by the tail (PHR test); (ii) asymmetry in resistance to
applied lateral gentle pressure from behind the shoul-
ders in the left and right directions (the rat was placed
on a flat surface). Ischemic rats showed less resistance
of the right part of the body (contralateral to the ische-
mic hemisphere). The right FL became stiff during the
push, while the left FL offered resistance; (iii) body
twisting when the rat was suspended by the tail (PHR
test); and, (iv) circling or inability to walk straight when
the rat was placed on a flat surface. The following 4-
score grading system was adopted: 0 = impairment in
(i), (ii), (iii), and (iv) (severe motor deficit); 1 = impair-
ment in (i), (ii), and (iii) (moderate motor deficit);
2 = impairment in (i) and (ii) (mild motor deficit);
3 = no deficit.
AT test
Two adhesive tapes (1 × 1 cm) were placed on the radial
aspect of both FLs alternating the order of their applica-
tion, i.e., right versus left. Both ATs were then pressed
slightly and simultaneously and rats were placed imme-
diately within a box and the time in seconds (precision
of measuring 1.0 s) needed to remove the ATs (latency)
and the order (preference) of FLs (left or right) for re-
moving the first AT was recorded. Rats were pre-trained
(five trials for five successive days) to obtain optimal
level of performance (latency ≤28 s) and to achieve ab-
sence of asymmetry between right and left FL perform-
ance before stroke induction. The experimenter was
blind to the rat group (Et-1, sham-operated, WT or
Grm2 mutant). A trial ended when three min had
elapsed without removing of either of the two ATs. For
the preference, the ipsilateral (Ipsi) and contralateral
(Contra) values referred to mean percentage of trials
(out of five for each pre- or post-Et-1 session) in which
the rat removed the AT placed on the left or right FL,
respectively. For the latency, the Ipsi and Contra values
referred to mean time (for five trials in each pre- or
post-Et-1 session) needed to remove the AT from the ip-
silateral or contralateral FL, respectively.
Asymmetry assessment in behavioural performance (AT
and PHR tests)
The asymmetry in behavioural performance was assessed
by means of the Laterality Index (LI) = (Ipsi – Contra) /
(Ipsi + Contra). For the PHR test, the range of LI was
between 0 (normal PHR, equal scores for the right and
left sides of the body) and +1.0 (maximum ischemic def-
icit, PHR score for the right, contralateral side was 0).
For the preference in the AT test, having in mind that
the range of the preference was between 0% and 100%,
the range of LI was from +1.0 (full ipsilateral preference
or maximum ischemic deficit) through 0.0 (normal per-
formance) to - 1.0 (full contralateral preference). For the
latency in the AT test, having in mind that the range of
the latency was between 1.0 s and (equal to the precision
of measuring) 180.0 s, the range of LI was from approxi-
mately +1.00 (fast contralateral response and lack of
ipsilateral response) through 0.00 (equal responses of
both FLs, normal), to approximately −1.00 (fast ipsilat-
eral response and lack of contralateral response, max-
imum ischemic deficit). The time sessions were T0, 1,
24, 72 h, where T0 was mean value of LIs of Preference
or Latency before the Et-1 (or Saline) infusion on three
consecutive days, with five trials on each day. The values
of laterality index were normalized by subtracting the
control values (at T0).
Histological analysis
Mice and rats were sacrificed respectively at 48 and 72 h
post MCAO and brains were fixed in Carnoy’s solution,
embedded in paraffin, and sectioned at 10 μm. Sections
regularly spaced every 550 μm (through the extension of
the ischemic region) were deparaffinized and processed for
staining with thionin (Nissl staining for histological assess-
ment of neuronal degeneration). The infarct area was out-
lined at magnification of X 2.5 and measured with Scion
Image software (NIH, Bethesda, MD, USA), then the infarct
volume (V) was calculated by integrating the cross-
sectional area of damage on each level and the distance
between them: V = Σ (Ai x TS_x n), where Ai is the ische-
mic area measured at i-th section, the TS is the section
thickness (10 μm), and n is the number of sections between
two adjacent levels. In addition, we measured in rats the
infarct area at level of a single section (AP = + 0.2 mm from
bregma) in the S1FL, S1DZ, S1ULp, S2, GI/DI, AI and Cl.
Statistics
For the neurological test in mice and the PHR test in
rats, we used Kruskal-Wallis nonparametric ANOVA for
multiple unrelated samples (Statistical package Statistica
7.0, 2004, Statsoft, Tulsa, OK) to determine the overall
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group effect at each time point. Then Mann-Whitney U-
test (corrected for the small size of independent sam-
ples) was performed for the evaluation of the differences
between Et-1 and sham-operated rats, separately for WT
and Grm2 mutant rats. Friedman ANOVA by ranks and
subsequent Wilcoxon matched-pairs test for related
samples were used for evaluation of changes in neuro-
logical scores in mice and asymmetry in the PHR test in
rats as a function of time.
Statistical analysis of the grip strength test in mice and
asymmetry in the AT test in rats was performed by three-
way repeated measures Hotelling ANOVA (General
Linear Model, Statistica7.0, Statsoft) with factors: Group
(mGlu2+/+, mGlu2−/−), Side (Ipsilateral FL, Contralateral
FL) and Time (T0, 2, 24 and 48 h) in mice, and two-way
repeated measures Hotelling ANOVA for asymmetry in
AT preference and latency with factors: - Group (WT,
Grm2 mutant) and Time (T0, 1, 24 and 72 h) in rats. For
Post-hoc analysis we used Fisher’s LSD or Dunnett’s tests.
Student’s’ t test was used for the analysis of infarct vol-
umes in mice and rats (Statistica 7.0, Statsoft).
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